文献速递药物不良反应与药物警戒抗栓抗凝管理

FDA不良事件报告系统与Sentinel系统联合表征直接口服抗凝药相关皮肤小血管炎

Complementary Use of U.S. FDA's Adverse Event Reporting System and Sentinel System to Characterize Direct Oral Anticoagulants-Associated Cutaneous Small Vessel Vasculitis.
PubMed 文献 · Pharmacotherapy · 2020-11-08

研究利用FAERS描述DOAC暴露后CSVV的临床特征,并在Sentinel系统中分析2010至2018年成人DOAC暴露后CSVV病例。FAERS识别50例CSVV,约50%在暴露后10天内发生;Sentinel识别3659例,85%事件在10天内。两系统时间聚集性提示DOAC与CSVV可能存在因果关系。

要点

  • FAERS中50例DOAC相关CSVV,约50%在暴露后10天内发生。
  • Sentinel系统中3659例CSVV有DOAC暴露,85%事件在10天内。
  • 多数FAERS病例需住院(n=37),部分报告更换药物后好转。

核心结论

  • FAERS病例评估结合Sentinel系统病例的时间聚集性,提示DOAC与CSVV可能存在因果关系。

研究设计与样本

  • 研究查询FAERS中每种DOAC美国批准上市至2018年3月16日的所有CSVV病例。
  • 在Sentinel系统中,利用ICD-9和ICD-10诊断代码识别2010年1月1日至2018年6月30日期间既往90天内接受DOAC的30岁及以上成人新发CSVV病例。
  • 排除CSVV诊断前183天内存在特定自身免疫诊断证据的患者,并报告CSVV诊断前183天内的患者特征。

主要发现

  • FAERS中识别50例CSVV,涉及利伐沙班(n=26)、阿哌沙班(n=14)、达比加群(n=9)和依度沙班(n=1)。
  • 约50%的FAERS病例报告在DOAC暴露后10天内发生。
  • FAERS中具体分型以白细胞碎裂性血管炎为主(n=31),其次为过敏性紫癜(n=4)。
  • FAERS中多数病例需住院(n=37),26例报告在CSVV发生后更换致病药物。
  • Sentinel系统中识别3659例既往DOAC暴露的CSVV病例,85%的事件发生在10天内。

临床怎么用

  • 临床药师应警惕DOAC暴露后10天内出现的皮肤小血管炎表现,尤其是白细胞碎裂性血管炎。
  • 对疑似DOAC相关CSVV患者,可考虑评估更换抗凝药物,但需结合血栓风险个体化决策。

局限性

  • FAERS存在自发报告固有的报告偏倚和不完整性。
  • Sentinel系统基于诊断代码识别CSVV,可能存在错分。
  • 研究未量化不同DOAC之间CSVV的风险差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cutaneous small vessel vasculitis (CSVV) has been reported after exposure to direct oral anticoagulants (DOACs), such as dabigatran, rivaroxaban, apixaban, and edoxaban. OBJECTIVE: We used the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) to describe clinical characteristics associated with CSVV among DOAC-exposed patients. Furthermore, we characterized this signal in the Sentinel System to relate the clinical data from the individual FAERS cases to population-based electronic healthcare data. METHODS: We queried FAERS for all cases of CSVV associated with DOACs from U.S. approval date of each DOAC through March 16, 2018. Within the Sentinel System, we identified incident CSVV cases using ICD-9 and ICD-10 diagnosis codes among adults aged ≥ 30 years who received a DOAC in the prior 90 days between January 1, 2010, and June 30, 2018. We excluded patients with evidence of select autoimmune diagnoses in the 183 days prior to their CSVV diagnoses and reported patient characteristics in the 183-day period prior to CSVV diagnoses. RESULTS: In FAERS, we identified 50 cases of CSVV reported with rivaroxaban (n=26), apixaban (n=14), dabigatran (n=9), and edoxaban (n=1). Approximately 50% of the cases reported time to onset within 10 days after DOAC exposure. When specified, the predominant type of CSVV reported was leukocytoclastic vasculitis (n=31), followed by Henoch-Schonlein purpura (n=4). Hospitalization occurred in most of the cases (n=37). Switching of the offending agent after the development of CSVV was reported (n=26). Three rivaroxaban (n=3) cases and one dabigatran case (n=1) reported positive rechallenge. In the Sentinel system, we identified 3659 CSVV cases with prior DOAC exposure, with 85% of events occurring within 10 days. CONCLUSIONS: The assessment of FAERS cases, combined with the temporal clustering of the Sentinel System cases suggest a possible causal relationship of DOACs and CSVV. Future efforts should characterize the risk of CSVV among the various DOAC users.

来源:Pharmacotherapy,查看原文。版权归原作者所有。

引用

  1. Mohamoud M, Horgan C, Eworuke E, et al. Complementary Use of U.S. FDA's Adverse Event Reporting System and Sentinel System to Characterize Direct Oral Anticoagulants-Associated Cutaneous Small Vessel Vasculitis. Pharmacotherapy. 2020. PMID: 33090530. doi:10.1002/phar.2468

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。